tiprankstipranks
Sera Prognostics (SERA)
NASDAQ:SERA
US Market

Sera Prognostics (SERA) Earnings Dates, Call Summary & Reports

Compare
73 Followers

Earnings Data

Report Date
May 07, 2025
TBA Not Confirmed
Period Ending
2025 (Q1)
Consensus EPS Forecast
-0.23
Last Year’s EPS
-0.25
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Mar 19, 2025
|
% Change Since: -5.80%
|
Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements such as the successful PRIME study results and strong fundraising efforts, as well as plans for commercial expansion and strategic partnerships. However, these were balanced by challenges such as declining revenue and increased expenses, resulting in a neutral overall sentiment.
Company Guidance
During the Sera Prognostics conference call reviewing the fourth quarter of fiscal year 2024, the company shared several key financial and operational metrics and goals. Net revenue for the fourth quarter was reported at $24,000, a decrease from $41,000 in the same period of 2023, and total operating expenses increased by 6% to $9.4 million. The net loss for the quarter was $8.6 million, up from $7.9 million a year ago. The company highlighted the results of its PRIME study, which demonstrated a 25% reduction in neonatal mortality and morbidity, an 18% reduction in neonatal hospital stay, and a 20% reduction in NICU admissions. Sera Prognostics plans to further its commercialization efforts, with cash operating expenses expected to range between $30 million and $35 million in 2025, leveraging recent capital from a $57.5 million public offering. The company also discussed its strategy for achieving guideline inclusion, focusing on publishing more data, providing real-world evidence, and driving clinical adoption. Looking ahead, Sera plans to expand its commercial operations, including potential international expansion and further investment in its pipeline products.
Strong Results from PRIME Study
The PRIME study, conducted at 19 locations with 5,018 patients, showed a 25% reduction in neonatal mortality and morbidity index, an 18% reduction in neonatal length of hospital stay, and a 20% reduction in NICU admissions.
Successful Fundraising and Strong Balance Sheet
The company successfully raised $57.5 million in a public follow-on offering, securing a cash runway through 2028, with cash, cash equivalents, and available-for-sale securities at $68.2 million as of December 31, 2024.
Expansion Plans and New Board Appointment
Plans to expand commercialization efforts in the US and explore international expansion, particularly in the European Union. Appointment of Jeff Elliott to the Board of Directors, bringing expertise from the medical diagnostics industry.
Focus on Medicaid and Public Health Partnerships
Targeting states with high preterm birth rates for Medicaid partnerships to demonstrate cost savings and impact, with specific focus on Nevada and Louisiana.
---

Sera Prognostics (SERA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

SERA Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 07, 20252025 (Q1)
-0.23 / -
-0.25
Mar 19, 20252024 (Q4)
-0.24 / -0.25
-0.250.00% (0.00)
Nov 06, 20242024 (Q3)
-0.22 / -0.24
-0.23-4.35% (>-0.01)
Aug 07, 20242024 (Q2)
-0.26 / -0.25
-0.3426.47% (+0.09)
May 08, 20242024 (Q1)
-0.27 / -0.25
-0.3426.47% (+0.09)
Mar 20, 20242023 (Q4)
-0.26 / -0.25
-0.3119.35% (+0.06)
Nov 08, 20232023 (Q3)
-0.34 / -0.23
-0.3534.29% (+0.12)
Aug 09, 20232023 (Q2)
-0.36 / -0.34
-0.378.11% (+0.03)
May 10, 20232023 (Q1)
-0.38 / -0.34
-0.415.00% (+0.06)
Mar 22, 20232022 (Q4)
-0.36 / -0.31
-0.4124.39% (+0.10)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

SERA Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 19, 2025$4.14$3.93-5.07%
Nov 06, 2024$8.74$7.63-12.70%
Aug 07, 2024$7.40$7.41+0.14%
May 08, 2024$9.30$9.79+5.27%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Sera Prognostics (SERA) report earnings?
Sera Prognostics (SERA) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
    What is Sera Prognostics (SERA) earnings time?
    Sera Prognostics (SERA) earnings time is at May 07, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is SERA EPS forecast?
          SERA EPS forecast for the fiscal quarter 2025 (Q1) is -0.23.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis